January 31st 2022
BSCB Dev
Drug discovery and development company EPICS Therapeutics announced today that its Board of Directors has appointed Franz Obermayr, Ph.D., as the Company's Chief Executive Officer. He will also join EPICS Therapeutics Board of Directors. Franz Obermayr will succeed Jean Combalbert, who will continue to serve on the EPICS therapeutics Board of Directors and support the team and Franz Obermayr as a consultant to facilitate a smooth change over process.
Read Pdf